Delving into the Latest Updates on European University Cyprus Ltd. with Synapse

Overview

The goal of this randomised clinical trial is to evaluate the effects of exercise with blood flow restriction (BFR) in patients with a complete anterior cruciate ligament (ACL) rupture.
The main questions it aims to answer are:
1. Does blood flow restriction adds any additional benefits to conservative treatment of the ACL?
2. Does bracing promotes spontaneous healing to the ACL
Researchers will compare bracing and BFR to bracing and sham BFR to see if the intervention provides any additional benefits to the conservative management of this injury.
Participants will:
1. Use a knee brace for 6 weeks with adjustments according to protocol
2. Follow and identical exercise plan with either BFR (intervention group) or BFR sham (control group)
3. Follow a home based exercise program.

Start Date01 Feb 2025

Sponsor / Collaborator

European University Cyprus Ltd.

NCT05956288

/ CompletedNot ApplicableIIT

The Hypoalgesic Effects of BFR Training in Nonspecific Shoulder Pain. A Study Protocol of a Crossover Randomized Controlled Clinical Trial

The primary objective of the present study is to evaluate if a single acute BFR low load- exercise bout would reduce pain in patients with nonspecific shoulder pain and whether the potential hypoalgesia will be maintained after a 45-minute physical therapy shoulder exercise session. BFR exercise will be compared to a sham BFR exercise protocol. We hypothesize that the participants in the BFR group in will experience reduced pain and will be able to complete a scapula and rotator cuff muscles exercise loading program with reduced pain until the end of the exercise program.

Start Date27 Feb 2024

Sponsor / Collaborator

European University Cyprus Ltd.

100 Clinical Results associated with European University Cyprus Ltd.

Login to view more data

0 Patents (Medical) associated with European University Cyprus Ltd.

Login to view more data

2,413

Literatures (Medical) associated with European University Cyprus Ltd.

31 Dec 2025·The Journal of Maternal-Fetal & Neonatal Medicine

Pregnancy-associated plasma protein A (PAPP-A) as a first trimester serum biomarker for preeclampsia screening: a systematic review and meta-analysis

Review

Author: Al-Jazrawi, Zeyad ; Tzanaki, Ismini ; Lymperopoulou, Charoula ; Makrigiannakis, Antonis ; Agouridis, Aris P.

OBJECTIVEThe aim of this study is to systematically examine the role of the pregnancy-associated plasma protein A (PAPP-A) serum biomarker in the first trimester screening of preeclampsia (PE).MATERIALS AND METHODSA systematic search of the literature was conducted on PubMed via Medline, and Cochrane Library up to 8 November 2022, for prospective studies evaluating PAPP-A serum levels in first trimester pregnant women as a screening biomarker for PE. Eligible were all prospectively designed case-control or cohort studies, published in English. Two investigators independently examined the studies and the studies' characteristics were extracted. Newcastle-Ottawa Scale (NOS) for case-control and cohort studies were applied to assess the risk of bias. For the quantitative analysis of the studies, a meta-analysis was also performed.RESULTSA total of 22 studies including 33,651 pregnant women were assessed, of whom, 2001 were diagnosed with PE. A meta-analysis was performed, showing that PAPP-A levels in the first trimester were significantly lower in early onset preeclamptic women (MD: -0.24, 95% CI: -0.37, -0.11, p = .0002), late onset (MD: -0.15, 95% CI: -0.25, -0.05, p = .03), and total preeclamptic cases (MD = -0.17, 95% CI = -0.23, -0.11, p < .00001) when compared with controls.CONCLUSIONSOur results suggest that PAPP-A can be a promising predictor in early screening for PE; hence, women at risk can be diagnosed early in their pregnancy stage and benefit from individualized PE treatment before it progresses.

31 Dec 2025·Cogent Social Sciences

Comparative analysis of economic responses: Lebanon vs. Russia

Author: Abou Ltaif, Samar ; Mihai-Yiannaki, Simona

01 Dec 2025·Current Cardiology Reports

Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease

Review

Author: Katsiki, Niki ; Vrablik, Michal ; Kolovou, Genovefa

PURPOSE OF REVIEWIn recent years, the terms "metabolic associated fatty liver disease-MAFLD" and "metabolic dysfunction-associated steatotic liver disease-MASLD" were introduced to improve the encapsulation of metabolic dysregulation in this patient population, as well as to avoid the negative/stigmatizing terms "non-alcoholic" and "fatty".RECENT FINDINGSThere is evidence suggesting links between MASLD and coronary heart disease (CHD), heart failure (HF), atrial fibrillation (AF), stroke, peripheral artery disease (PAD) and chronic kidney disease (CKD), although the data for HF, AF, stroke and PAD are scarcer. Physicians should consider the associations between MASLD and CV diseases in their daily practice. Based on this knowledge and current guidelines, they should also assess and manage CV risk/co-morbidities in such patients. It is important to further investigate the impact of MASLD on CV outcomes, a knowledge that will help to elucidate the clinical implications of this "novel" liver entity.

100 Deals associated with European University Cyprus Ltd.

Login to view more data

100 Translational Medicine associated with European University Cyprus Ltd.

Login to view more data